Teclison Ltd.

Teclison Ltd. logo
🇺🇸United States
Ownership
Holding
Established
2014-01-01
Employees
11
Market Cap
-
Website
http://www.teclison.com

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

First Posted Date
2021-01-08
Last Posted Date
2024-11-22
Lead Sponsor
Teclison Ltd.
Target Recruit Count
110
Registration Number
NCT04701476
Locations
🇺🇸

University of California, Irvine Medical Center, Orange, California, United States

🇨🇳

Chung Shan Medical University Hospital, Taichung, Taiwan

🇨🇳

China Medical University Hsinchu Hospital, Hsinchu, Taiwan

Combination of TATE and PD-1 Inhibitor in Liver Cancer

First Posted Date
2017-08-24
Last Posted Date
2024-11-22
Lead Sponsor
Teclison Ltd.
Target Recruit Count
54
Registration Number
NCT03259867
Locations
🇺🇸

University of California, Irvine, Orange, California, United States

🇺🇸

University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States

🇺🇸

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

TATE Versus TACE in Intermediate Stage HCC

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2017-05-09
Last Posted Date
2024-11-22
Lead Sponsor
Teclison Ltd.
Target Recruit Count
6
Registration Number
NCT03145558
Locations
🇺🇸

University of California, Irvine, Irvine, California, United States

🇺🇸

Oregon Health Science University, Portland, Oregon, United States

🇺🇸

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

First Posted Date
2014-06-25
Last Posted Date
2024-11-22
Lead Sponsor
Teclison Ltd.
Target Recruit Count
25
Registration Number
NCT02174549
Locations
🇺🇸

Stanford University, Palo Alto, California, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath